Literature DB >> 16167918

A comparison of the human papillomavirus test and Papanicolaou smear as a second screening method for women with minor cytological abnormalities.

Sonia Andersson1, Lena Dillner, Kristina Elfgren, Miriam Mints, Maria Persson, Eva Rylander.   

Abstract

BACKGROUND: Of the estimated one million Papanicolaou (pap) smears performed annually in Sweden, about 4% show any degree of abnormality. Approximately, 1% of these cases contain moderate or severe atypia (high-grade squamous intraepithelial lesions) and the rest contain low-grade atypia. Recommendations for the management of minor abnormalities vary in various parts of Sweden. Generally, a second Pap smear is obtained 4-6 months after the first one showing low-grade atypia. The aim of this study is to compare the sensitivity of human papilloma virus (HPV)-DNA testing for the detection of cervical intraepithelial neoplasia (CIN) 2-3 with that of a second Pap smear in women, who had low-grade atypia in their first Pap smear.
METHODS: Women with low-grade atypia in the Stockholm area, detected at a population-based cytology screening, were enrolled. A repeat Pap smear, HPV test, and colposcopically directed biopsies were obtained. For the detection of HPV, Hybrid Capture II (HC II) was used.
RESULTS: The HPV-DNA test was positive in 66% of the 177 participating women. The sensitivity of the second Pap smear and HPV-DNA test to detect CIN 2-3 was 61 (95% CI = 45-74) and 82% (95% CI = 67-91), respectively. The positive and negative predictive values of HPV testing were 27 (95% CI = 18-35) and 89% (95% CI = 80-97), respectively.
CONCLUSIONS: In Sweden, a second Pap smear is often obtained for the follow-up of women with low-grade atypia. The results of our study show that compared to the second Pap smear, HPV testing with HC II is a more sensitive method for detecting high-grade lesions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16167918     DOI: 10.1111/j.0001-6349.2005.00702.x

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  4 in total

1.  Five-year risks of CIN 2+ and CIN 3+ among women with HPV-positive and HPV-negative LSIL Pap results.

Authors:  Hormuzd A Katki; Mark Schiffman; Philip E Castle; Barbara Fetterman; Nancy E Poitras; Thomas Lorey; Li C Cheung; Tina Raine-Bennett; Julia C Gage; Walter K Kinney
Journal:  J Low Genit Tract Dis       Date:  2013-04       Impact factor: 1.925

2.  Diagnostic value of MCM2 immunocytochemical staining in cervical lesions and its relationship with HPV infection.

Authors:  Jian Zheng
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

3.  Type distribution, viral load and integration status of high-risk human papillomaviruses in pre-stages of cervical cancer (CIN).

Authors:  S Andersson; H Safari; M Mints; I Lewensohn-Fuchs; U Gyllensten; B Johansson
Journal:  Br J Cancer       Date:  2005-06-20       Impact factor: 7.640

4.  Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate.

Authors:  Marc Arbyn; Pierre Martin-Hirsch; Frank Buntinx; Marc Van Ranst; Evangelos Paraskevaidis; Joakim Dillner
Journal:  J Cell Mol Med       Date:  2009-01-23       Impact factor: 5.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.